AgomAb Therapeutics NV (AGMB) vs C4 Therapeutics (CCCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($447.2 million vs $388.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | CCCC |
|---|---|---|
| Share price | $9.08 | $3.16 |
| Market cap | $447.17M | $388.76M |
| 1-day change | -1.52% | +10.88% |
| YTD return | — | +65.45% |
| 1-year return | — | +31.12% |
| 5-year return | — | -92.80% |
| EPS (TTM) | $-2.08 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $5.17 |
| 52-week low | $7.97 | $1.69 |
| Distance from 52-week high | -49.05% | -38.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.87% | +306.96% |
| Average volume | 140.67K | 2.38M |
| Shares outstanding | 49.25M | 123.03M |
| Employees | 62 | 104 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Healthcare · Biotechnology · 62 employees
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
AGMB vs CCCC FAQ
Which is bigger, AgomAb Therapeutics NV or C4 Therapeutics?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $447.17M compared with $388.76M for C4 Therapeutics (CCCC).
Are AgomAb Therapeutics NV and C4 Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.